vs
Side-by-side financial comparison of EURONET WORLDWIDE, INC. (EEFT) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
EURONET WORLDWIDE, INC. is the larger business by last-quarter revenue ($1.1B vs $346.4M, roughly 3.2× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 4.7%, a 23.4% gap on every dollar of revenue. On growth, EURONET WORLDWIDE, INC. posted the faster year-over-year revenue change (5.9% vs 4.8%). EURONET WORLDWIDE, INC. produced more free cash flow last quarter ($434.3M vs $209.9M). Over the past eight quarters, EURONET WORLDWIDE, INC.'s revenue compounded faster (13.7% CAGR vs 1.5%).
Euronet Worldwide is an American provider of global electronic payment services with headquarters in Leawood, Kansas. It offers automated teller machines (ATM), point of sale (POS) services, credit/debit card services, currency exchange and other electronic financial services and payments software. Among others, it provides the prepaid subsidiaries Transact, PaySpot, epay, Movilcarga, TeleRecarga and ATX.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
EEFT vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $346.4M |
| Net Profit | $51.8M | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | 9.1% | 36.1% |
| Net Margin | 4.7% | 28.1% |
| Revenue YoY | 5.9% | 4.8% |
| Net Profit YoY | 14.3% | — |
| EPS (diluted) | $0.97 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $1.1B | $339.0M | ||
| Q3 25 | $1.1B | $327.3M | ||
| Q2 25 | $1.1B | $321.4M | ||
| Q1 25 | $915.5M | $330.6M | ||
| Q4 24 | $1.0B | $348.5M | ||
| Q3 24 | $1.1B | $345.5M | ||
| Q2 24 | $986.2M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $51.8M | $44.7M | ||
| Q3 25 | $122.0M | $38.7M | ||
| Q2 25 | $97.6M | $34.0M | ||
| Q1 25 | $38.4M | $58.0M | ||
| Q4 24 | $45.3M | $37.5M | ||
| Q3 24 | $151.5M | $33.8M | ||
| Q2 24 | $83.1M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 9.1% | 19.9% | ||
| Q3 25 | 17.0% | 17.9% | ||
| Q2 25 | 14.8% | 16.8% | ||
| Q1 25 | 8.2% | 21.6% | ||
| Q4 24 | 11.7% | 16.9% | ||
| Q3 24 | 16.6% | 15.0% | ||
| Q2 24 | 13.6% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 4.7% | 13.2% | ||
| Q3 25 | 10.6% | 11.8% | ||
| Q2 25 | 9.1% | 10.6% | ||
| Q1 25 | 4.2% | 17.5% | ||
| Q4 24 | 4.3% | 10.8% | ||
| Q3 24 | 13.8% | 9.8% | ||
| Q2 24 | 8.4% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.97 | $0.95 | ||
| Q3 25 | $2.75 | $0.81 | ||
| Q2 25 | $2.27 | $0.70 | ||
| Q1 25 | $0.85 | $1.17 | ||
| Q4 24 | $0.96 | $0.74 | ||
| Q3 24 | $3.21 | $0.66 | ||
| Q2 24 | $1.73 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0B | $245.4M |
| Total DebtLower is stronger | $1.0B | $1.2B |
| Stockholders' EquityBook value | $1.3B | $796.3M |
| Total Assets | $6.5B | $2.4B |
| Debt / EquityLower = less leverage | 0.79× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $1.0B | $363.4M | ||
| Q3 25 | $1.2B | $296.4M | ||
| Q2 25 | $1.3B | $292.9M | ||
| Q1 25 | $1.4B | $306.8M | ||
| Q4 24 | $1.3B | $320.8M | ||
| Q3 24 | $1.5B | $299.3M | ||
| Q2 24 | $1.3B | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $1.3B | $911.5M | ||
| Q3 25 | $1.3B | $849.2M | ||
| Q2 25 | $1.4B | $882.3M | ||
| Q1 25 | $1.3B | $820.8M | ||
| Q4 24 | $1.2B | $906.9M | ||
| Q3 24 | $1.4B | $878.9M | ||
| Q2 24 | $1.2B | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $6.5B | $2.5B | ||
| Q3 25 | $6.3B | $2.4B | ||
| Q2 25 | $6.6B | $2.5B | ||
| Q1 25 | $6.1B | $2.5B | ||
| Q4 24 | $5.8B | $2.5B | ||
| Q3 24 | $6.3B | $2.5B | ||
| Q2 24 | $6.1B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 0.79× | 1.34× | ||
| Q3 25 | 0.85× | 1.44× | ||
| Q2 25 | 0.74× | 1.39× | ||
| Q1 25 | 1.46× | 1.49× | ||
| Q4 24 | 0.92× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $559.8M | $293.2M |
| Free Cash FlowOCF − Capex | $434.3M | $209.9M |
| FCF MarginFCF / Revenue | 39.2% | 60.6% |
| Capex IntensityCapex / Revenue | 11.3% | 9.5% |
| Cash ConversionOCF / Net Profit | 10.81× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $722.3M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $559.8M | $93.6M | ||
| Q3 25 | $197.3M | $111.3M | ||
| Q2 25 | $182.9M | $17.4M | ||
| Q1 25 | $1.7M | $116.6M | ||
| Q4 24 | $732.8M | $43.8M | ||
| Q3 24 | $440.3M | $48.8M | ||
| Q2 24 | $182.2M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $434.3M | $87.2M | ||
| Q3 25 | $161.2M | $106.3M | ||
| Q2 25 | $148.3M | $13.6M | ||
| Q1 25 | $-21.5M | $100.9M | ||
| Q4 24 | $615.6M | $35.2M | ||
| Q3 24 | $414.5M | $39.4M | ||
| Q2 24 | $148.8M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 39.2% | 25.7% | ||
| Q3 25 | 14.1% | 32.5% | ||
| Q2 25 | 13.8% | 4.2% | ||
| Q1 25 | -2.3% | 30.5% | ||
| Q4 24 | 58.8% | 10.1% | ||
| Q3 24 | 37.7% | 11.4% | ||
| Q2 24 | 15.1% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 11.3% | 1.9% | ||
| Q3 25 | 3.2% | 1.5% | ||
| Q2 25 | 3.2% | 1.2% | ||
| Q1 25 | 2.5% | 4.7% | ||
| Q4 24 | 11.2% | 2.5% | ||
| Q3 24 | 2.3% | 2.7% | ||
| Q2 24 | 3.4% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 10.81× | 2.09× | ||
| Q3 25 | 1.62× | 2.88× | ||
| Q2 25 | 1.87× | 0.51× | ||
| Q1 25 | 0.04× | 2.01× | ||
| Q4 24 | 16.18× | 1.17× | ||
| Q3 24 | 2.91× | 1.44× | ||
| Q2 24 | 2.19× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EEFT
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
